CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioAxone BioSciences, Inc., a biotechnology company focused on developing innovative drugs to treat neurotrauma and neurovascular disorders today announced that CEO Lisa McKerracher, PhD, will be a platform speaker on the Scientific Program, “Update on Clinical Trials in SCI” at NeuroTrauma2018, The 3rd Joint Symposium of the International and National Neurotrauma Societies and AANS/CNS Section on Neurotrauma and Critical Care, August 15.
“It is now understood that PTEN is an intrinsic barrier to regeneration of neurons in the central nervous system,” said Dr. McKerracher. “We are honored to have the opportunity to share the way in which we are investigating a therapeutically relevant PTEN gene silencing strategy to promote axon regeneration after neurotrauma.”
Spinal cord injury is a devastating condition that generally results in sensory and motor paralysis below the level of the injury. Most spinal cord injuries are in the cervical (neck) region of the spinal cord. Even very small improvements in neurological recovery in these patients could restore arm and hand mobility, significantly impacting quality of life. Despite the serious nature of spinal cord injury and potential for therapeutic benefit, there are no drugs on the market to repair neuronal damage and reduce paralysis after spinal cord injury.
About BioAxone BioSciences
BioAxone BioSciences is a clinical-stage biotechnology company based in Cambridge, MA, and is developing innovative drugs to restore neurological function for patients with spinal cord injuries and neurovascular disorders. The company also has preclinical programs in restoring epithelial barriers in gastrointestinal disease and in glaucoma. BioAxone is led by a team of scientists renowned for their work on axon regeneration, diseases involving Rho/ROCK signaling and cell barrier function. For more information, visit http://www.bioaxonebio.com and follow the company on Twitter at @BioAxone.